Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Crescent Pharma Outsources Drug Safety Operations To APC
Reportedly, the APC’s team of pharmacovigilance experts provide a complete range of services using the latest technology. The service is based on a fully electronic platform which is
Reportedly, the APC’s team of pharmacovigilance experts provide a complete range of services using the latest technology. The service is based on a fully electronic platform which is
The company aims to improve existing immunoassays by providing additional sensitivity to currently available antibody-based test, as well as allowing researchers to monitor new markers that are not
Bedford is expected to supply Fluconazole injection sterile iso-osmotic solution containing 2mg/ml of fluconazole in glass vials in the following presentations: Vials containing either 100mg, 200mg or 400mg
The company is currently completing Phase 2 studies of Voreloxin as a single-agent or in combination with cytarabine in acute myeloid leukemia (AML) and expects to begin Phase
Additionally, Evotec is expected to provide a full range of neurological research activities and expertise to CHDI, including integrated biology and chemistry supported by compound and library management,
The company said that Davunetide’s potential as a treatment for PSP was confirmed in both animal studies and phase II human clinical trials in patients with amnestic mild
The decision was based on results from the clinical trial, OGT 918-007, and two multicenter NP-C disease cohort studies and clinical trials in related lysosomal storage disorders for
Rapiacta, licensed from US-based BioCryst Pharmaceuticals, has been developed by Shionogi in Japan. Shionogi received approval for both single dose administration for adult uncomplicated seasonal influenza infection as
GLP-1 (Glucagon-Like Peptide-1) is a natural hormone involved in controlling blood sugar levels. It stimulates the release of insulin only when blood sugar levels become too high. In
In response to the economic pressure, Lonza is strengthening its platform in Asia and will close the sites of Conshohocken (Riverside), PA (US), Shawinigan (CDN), and Wokingham (UK)